Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02335944
Recruitment Status : Recruiting
First Posted : January 12, 2015
Last Update Posted : January 11, 2022
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )